Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
Telix today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated…
Read moreNews & Views
TLX400 Therapy Published in Journal of Nuclear Medicine
Telix today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in the Journal of Nuclear Medicine. TLX400 demonstrated clinical antitumor activity with a manageable safety…
Read more
Telix Announces Record-Breaking Presence at EANM 2025
Telix today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Barcelona…
Read more
CMS Grants Transitional Pass-Through Status for Gozellix
Telix today announces that the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide…
Read more
IMRA Surgical Announces Collaboration with Telix Pharmaceuticals to Advance Radio-Guided Surgery Education and Training
News,
Telix today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68…
Read more
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
Telix today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68…
Read more
Telix and FDA Agree on Resubmission Pathway for TLX101-CDx (Pixclara®) U.S. NDA
Telix today announces that it has reached agreement with the United States (U.S.) Food and Drug Administration (FDA) regarding resubmission of its New Drug Application (NDA) for TLX101-CDx (Floretyrosine F18…
Read more
Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Spain
News,
Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Spain by AEMPS for the detection…
Read more
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
Telix today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August…
Read more
Telix H1 2025 Results: Investor Webcast Notification
Telix today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August…
Read more